Paige

Executive Summary

Paige is a pioneering AI company that leverages foundation models to transform cancer diagnostics and care. Founded in 2017 and headquartered in New York, Paige has developed large-scale AI models that set new benchmarks in computational pathology. By applying advanced machine learning to digitized pathology slides, the company aims to improve diagnostic accuracy, accelerate treatment decisions, and ultimately enhance patient outcomes. As one of the early movers in AI-powered pathology, Paige has established a strong technological moat through its proprietary foundation models, which are trained on vast datasets of cancer tissue. The company's platform has the potential to reduce pathologist workload, standardize diagnoses, and uncover novel biomarkers for drug development. With a focus on clinical integration and regulatory clearance, Paige is well-positioned to capture value in the growing digital pathology market. The company's collaborations with leading cancer centers and pharmaceutical partners underscore its credibility and path to commercialization. While the regulatory pathway remains a key risk, Paige's deep expertise in AI and oncology positions it as a leader in the next wave of precision medicine. The convergence of AI, digital pathology, and expanding cancer care needs creates a favorable tailwind for the company's growth. Paige's ability to secure further funding, partnerships, and FDA clearances will be critical in realizing its vision of transforming cancer care through AI.

Upcoming Catalysts (preview)

• Q4 2026FDA Clearance for AI Diagnostic Tools65% success
• Q2 2026Strategic Partnership with a Major Pharma Company75% success
• Q3 2026Series C or D Funding Round80% success